- Home
- PAC vs EXEL Comparison
PAC vs EXEL Comparison
Compare PAC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAC
- EXEL
- Stock Information
- Founded
- PAC 1998
- EXEL 1994
- Country
- PAC Mexico
- EXEL United States
- Employees
- PAC N/A
- EXEL N/A
- Industry
- PAC Aerospace
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAC Consumer Discretionary
- EXEL Health Care
- Exchange
- PAC Nasdaq
- EXEL Nasdaq
- Market Cap
- PAC 10.4B
- EXEL 9.8B
- IPO Year
- PAC 2006
- EXEL 2000
- Fundamental
- Price
- PAC $230.35
- EXEL $43.04
- Analyst Decision
- PAC Buy
- EXEL Buy
- Analyst Count
- PAC 6
- EXEL 18
- Target Price
- PAC $207.50
- EXEL $38.76
- AVG Volume (30 Days)
- PAC 82.2K
- EXEL 3.9M
- Earning Date
- PAC 07-22-2025
- EXEL 05-13-2025
- Dividend Yield
- PAC 3.35%
- EXEL N/A
- EPS Growth
- PAC N/A
- EXEL 237.58
- EPS
- PAC 0.86
- EXEL 2.20
- Revenue
- PAC $1,435,598,195.00
- EXEL $2,298,922,000.00
- Revenue This Year
- PAC $57.91
- EXEL $10.39
- Revenue Next Year
- PAC $8.28
- EXEL $10.74
- P/E Ratio
- PAC $26.60
- EXEL $19.53
- Revenue Growth
- PAC 14.67
- EXEL 24.49
- 52 Week Low
- PAC $146.62
- EXEL $20.40
- 52 Week High
- PAC $234.21
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- PAC 62.01
- EXEL 59.93
- Support Level
- PAC $223.43
- EXEL $42.21
- Resistance Level
- PAC $231.21
- EXEL $43.75
- Average True Range (ATR)
- PAC 5.62
- EXEL 1.60
- MACD
- PAC -0.41
- EXEL -0.09
- Stochastic Oscillator
- PAC 70.12
- EXEL 53.96
About PAC Grupo Aeroportuario Del Pacifico S.A. B. de C.V. Grupo Aeroportuario Del Pacifico S.A. de C.V. (each representing 10 Series B shares)
Grupo Aeroportuario del Pacifico SAB de CV is engaged in the construction, development, and operation of airports in Mexico. The company's segment includes Guadalajara; Tijuana; Puerto Vallarta; San Jose del Cabo; Montego Bay; Hermosillo; Guanajuato and Other Airports. It generates maximum revenue from the Guadalajara segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.